

**Investment in US-based VLP Therapeutics and  
Commencement of Discussions for Potential Collaboration**

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; Managing Director & CEO: Jin Shiomura) underwrote a third-party allocation of new shares of VLP Therapeutics, Inc. (Headquarter: Gaithersburg, Maryland, USA; CEO: Wataru Akahata).

Separately, Nobelpharma has entered into a memorandum of understanding on potential collaboration with VLP. Under this memorandum, the two companies agreed on the direction of the collaboration toward early initiation of clinical development and commercialization of prophylactic vaccines against infectious diseases such as malaria and dengue fever.

With the shared understanding that the common mission of the two companies to contribute to society by providing new vaccines against infectious diseases can be achieved more quickly and efficiently from comprehensive collaboration in the field of infectious diseases, both companies are desirous of cooperating widely in development, marketing approval application, post-marketing safety, and production management of preventive vaccine for infectious diseases, and therefore started discussions with a possibility of comprehensive business cooperation also in view.

Nobelpharma is committed to continue contributing to society through the provision of unmet needs pharmaceuticals and medical devices.

[Contact]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24 Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800